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BACKGROUND AND PURPOSE
Epilepsy is the most prevalent neurological disease and is characterized by recurrent seizures. Here, we investigate (i) the
anticonvulsant profiles of cannabis-derived botanical drug substances (BDSs) rich in cannabidivarin (CBDV) and containing
cannabidiol (CBD) in acute in vivo seizure models and (ii) the binding of CBDV BDSs and their components at cannabinoid
CB1 receptors.
EXPERIMENTAL APPROACH
The anticonvulsant profiles of two CBDV BDSs (50–422 mg·kg−1) were evaluated in three animal models of acute seizure.
Purified CBDV and CBD were also evaluated in an isobolographic study to evaluate potential pharmacological interactions.
CBDV BDS effects on motor function were also investigated using static beam and grip strength assays. Binding of CBDV
BDSs to cannabinoid CB1 receptors was evaluated using displacement binding assays.
KEY RESULTS
CBDV BDSs exerted significant anticonvulsant effects in the pentylenetetrazole (≥100 mg·kg−1) and audiogenic seizure models
(≥87 mg·kg−1), and suppressed pilocarpine-induced convulsions (≥100 mg·kg−1). The isobolographic study revealed that the
anticonvulsant effects of purified CBDV and CBD were linearly additive when co-administered. Some motor effects of CBDV
BDSs were observed on static beam performance; no effects on grip strength were found. The Δ9-tetrahydrocannabinol and
Δ9-tetrahydrocannabivarin content of CBDV BDS accounted for its greater affinity for CB1 cannabinoid receptors than purified
CBDV.
CONCLUSIONS AND IMPLICATIONS
CBDV BDSs exerted significant anticonvulsant effects in three models of seizure that were not mediated by the CB1
cannabinoid receptor and were of comparable efficacy with purified CBDV. These findings strongly support the further clinical
development of CBDV BDSs for the treatment of epilepsy.
Abbreviations
AED, antiepileptic drug; BDS, botanical drug substance; CBD, cannabidiol; CBDV, cannabidivarin; pCB,
phytocannabinoid; PTZ, pentylenetetrazole; Δ9-THC, Δ9-tetrahydrocannabinol; Δ9-THCV, Δ9-tetrahydrocannabivarin
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Introduction
Epilepsy is a chronic neurological disorder characterized by
recurrent seizures, which affects approximately 50 million
people worldwide (Leonardi and Ustun, 2002). Epilepsy’s
co-morbidities include cognitive decline, depressive disorders
and schizophrenia (Hermann et al., 2000; Kanner et al.,
2012), which are worsened by poorly controlled seizures
(Perucca et al., 2000). There are many treatments available
(BNF, 2011); however, all have notable side effects (Ortinski
and Meador, 2004; Schachter, 2007) and ∼30% of the cases
remain pharmacoresistant, resulting in poorly controlled sei-
zures (Hitiris et al., 2007). This represents a major unmet
clinical need for new well-tolerated antiepileptic drugs (AEDs)
able to control previously pharmacoresistant epilepsies.
We and others have previously reported that cannabidiol
(CBD), a non-psychoactive phytocannabinoid (pCB) of the
cannabis plant, is anticonvulsant in several in vivo seizure
models (Consroe et al., 1982; Wallace et al., 2001; Jones et al.,
2010; 2012) and in humans (Cunha et al., 1980). Similarly,
cannabidivarin (CBDV; the propyl analogue of CBD) is anti-
convulsant in vivo (Hill et al., 2012a). While the anticonvul-
sant mechanisms of CBD and CBDV are unidentified, their
anticonvulsant and tolerability profiles do not suggest inter-
action with the CB1 cannabinoid receptor (Wallace et al.,
2001; Jones et al., 2010; Hill et al., 2012a).
An increasing body of evidence suggests that cannabis
extracts enriched with a specific pCB can possess as much, or
more, pharmacological efficacy/potency than the purified
pCB (Wilkinson et al., 2003; Whalley et al., 2004; Ryan et al.,
2006; De Petrocellis et al., 2011; Sagredo et al., 2011;
Valdeolivas et al., 2012). As an example, amelioration of
spasticity associated with multiple sclerosis by Δ9-
tetrahydrocannabinol (THC) and CBD was greater in clinical
trials when these two pCBs were combined as two plant
extracts rather than as purified pCBs (Russo and Guy, 2006).
The apparent benefits of extracts may arise from polyphar-
macological effects of the pCBs (McPartland and Russo, 2001)
or the terpenoids present in cannabis extracts that possess
their own pharmacology and can modulate pCB effects to
enhance activity or reduce off-target effects (Formukong
et al., 1988; McPartland and Russo, 2001), the ‘entourage
effect’ (Russo, 2011).
Therefore, we extend our previous investigations of the
anticonvulsant effects of CBDV and CBD (Jones et al., 2010;
2012; Hill et al., 2012a) to assess the anticonvulsant potential
of extracts rich in CBDV and CBD [‘botanical drug sub-
stances’ (BDSs)]. Here, we test two such extracts: one with
pharmacologically significant ( Järbe et al., 2002; Hill
et al., 2010) Δ9-THC and Δ9-tetrahydrocannabivarin (THCV)
content (‘unmodified CBDV BDS’) and another with Δ9-THC
and Δ9-THCV removed (‘modified CBDV BDS’). This allows
assessment of the effects of Δ9-THC and Δ9-THCV on the
anticonvulsant and tolerability profiles of the compounds;
both Δ9-THC and Δ9-THCV can be anticonvulsant in their
own right (Corcoran et al., 1973; Fried and McIntyre, 1973;
Wallace et al., 2001; 2003; Hill et al., 2010), although there
are also some reports that Δ9-THC can be proconvulsant
(Chesher and Jackson, 1974; Karler and Turkanis, 1980).
Here, for the first time, we demonstrate significant anti-
convulsant actions of CBDV BDSs in rat and mouse in vivo
seizure models. Investigation of the interactions between the
principal constituent pCBs indicated that CBD and CBDV act
additively to suppress seizures. In motor assays, while
unmodified CBDV BDS adversely affected balance and coor-
dination at all doses, limited effects were only seen at the
highest dose of modified CBDV BDS; neither CBDV BDS
caused deficits in forelimb grip strength. Radioligand binding
indicated that the Δ9-THC/Δ9-THCV content of the unmodi-
fied CBDV BDS was responsible for the majority of CB1 can-
nabinoid receptor binding; parallel behavioural experiments
demonstrated that they were not required for anticonvulsant
effects.
Methods
Animals
All animals were housed on a 12 h light–dark cycle, with food
and water available ad libitum. Studies using male Wistar
Kyoto rats (70–110 g; Harlan, Bicester, UK) were undertaken
at the University of Reading. Mouse whole brain membranes
for binding studies (University of Aberdeen) were obtained
from adult (25–40 g) male MF1 mice (Harlan, Blackthorn,
UK). In both cases, work was conducted in accordance with
the Animals (Scientific Procedures) Act of 1986. Audiogenic
seizure experiments used DBA/2 mice (10–14 g, 3–4 weeks
old; Elevage Janvier, Le Genest-Saint-Isle, France), were
designed and analysed by the authors, and performed by
Porsolt Research Laboratory (Le Genest-Saint-Isle, France) in
accordance with the French legislation under licence from
the French Ministry for Agriculture and Fisheries. All animal
work was carried out in accordance with the ARRIVE guide-
lines for reporting experiments involving animals (Kilkenny
et al., 2010; McGrath et al., 2010); 595 rats and 290 mice were
used for in vivo studies in total.
Drug administration
Animals received either cannabis-derived CBDV BDSs or puri-
fied pCBs. pCBs (10–200 mg·kg−1) and cannabis-derived
CBDV BDSs (50–422 mg·kg−1; GW Pharmaceuticals Ltd,
Salisbury, UK); were suspended in ethanol, Cremophor EL
and saline [0.9% (w/v) NaCl, 2:1:17, respectively; all from
Sigma-Aldrich, Poole, UK]; and administered via i.p. injection
1 h prior to experimental procedures to achieve brain Tmax
(Deiana et al., 2012). Each experiment contained a control
group that received vehicle, to which other groups were com-
pared. In seizure experiments, group sizes were n = 10 for
mice and n = 15 for rats. Unmodified CBDV BDS contained
47.4% CBDV, 13.9% CBD, 1% Δ9-THC and 2.5% Δ9-THCV;
modified CBDV BDS lacked Δ9-THC/Δ9-THCV and contained
57.8% CBDV and 13.7% CBD; remaining content comprised
plant matter. A CBDV BDS with most pCB content removed
(termed BDS-pCB) contained no Δ9-THCV/Δ9-THC and 4.3%
CBDV and 0.1% CBD. For clarity, in vivo experiments are
numbered and detailed in Table 1 where the treatments used
in each experiment and the doses of CBDV, CBD, Δ9-THC and
Δ9-THCV received are outlined. The standardization and
reproducibility of all CBDV BDSs employed in this study
complied with the US Food and Drug Administration (FDA)
guidelines for botanical drug products (FDA, 2004).
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Rat seizure experiments
Pentylenetetrazole (PTZ; 85 mg·kg−1; Experiments 1.1–1.4 and
2.1) or pilocarpine (380 mg·kg−1; Experiments 4.1 and 4.2)
was administered i.p. 1 h after pCB/CBDV BDS/vehicle treat-
ment in 0.9% (w/v) NaCl. Methylscopolamine [1 mg·kg−1; in
0.9% (w/v) NaCl] was administered i.p. 45 min before pilo-
carpine to minimize pilocarpine’s peripheral effects. Seizure
activity was recorded (Farrimond et al., 2009) for 30 min
(PTZ) or 1 h (pilocarpine); video records were blinded and
subsequently coded offline using the Observer XT software
(Noldus, Wageningen, the Netherlands) and modified Racine
scales (PTZ: 0, normal behaviour; 0.5, abnormal behaviour; 1,
isolated myoclonic jerk; 2, atypical clonic seizure; 3, bilateral
forelimb clonus; 3.5, bilateral forelimb clonus with body
Table 1
Experimental design and pCB content of in vivo Experiments 1.1–4.2
Experiment/Figures Compound
Doses
(mg·kg−1)
CBDV/CBD content
(mg·kg−1)
THC/THCV content
(mg·kg−1)
Experiment 1.1, Figure 1A
and 1B
Modified CBDV BDS 50 29/7 0/0
100 58/14 0/0
200 116/27 0/0
275 159/38 0/0
346 200/47 0/0
Experiment 1.2, Figure 1C
and 1D
Purified CBDV 50 50/0 0/0
100 100/0 0/0
200 200/0 0/0
Modified CBDV BDS 50 29/7 0/0
100 58/14 0/0
200 116/27 0/0
Experiment 1.3, Figure 1E
and 1F
Purified CBDV + CBD Low 50/12 0/0
Mid 100/23 0/0
High 200/47 0/0
Modified CBDV BDS 50 50/12 0/0
100 100/23 0/0
200 200/47 0/0
Experiment 1.4, Figure 1G
and 1H
pCB-free BDS 50 2/<1 0/0
100 4/<1 0/0
200 9/<1 0/0
Experiments 2.1 and 2.2,
Figure 2A–F
Unmodified CBDV BDS 150 71/21 2/4
275 130/38 3/7
422 200/59 4/11
Modified CBDV BDS 150 87/21 0/0
275 159/38 0/0
346 200/47 0/0
Experiment 3.1, Figure 3A Unmodified CBDV BDS 50 24/7 1/1
100 47/14 1/3
200 95/28 2/5
Experiment 3.2, Figure 3B Modified CBDV BDS 50 29/7 0/0
100 58/14 0/0
200 116/27 0/0
Experiment 4.1, Figure 4A Unmodified CBDV BDS 100 47/14 1/3
200 95/28 2/5
300 142/42 3/8
Experiment 4.2, Figure 4B Modified CBDV BDS 200 116/27 0/0
Unmodified CBDV BDS 200 116/28 2/5
CBDV + CBD – 116/27 0/0
BJPCBDV-rich extracts are anticonvulsant
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twist; 4, tonic–clonic seizure with suppressed tonic phase; 5,
fully developed tonic–clonic seizure. Pilocarpine: 0, normal
behaviour; 1, mouth clonus; 2, unilateral forelimb clonus; 3,
bilateral forelimb clonus; 4, bilateral forelimb clonus with
rearing and falling; 4.5, tonic–clonic convulsions; 5, tonic–
clonic convulsions with righting reflex lost). In pilocarpine
experiments, purified CBDV was added to unmodified CBDV
BDS to match the CBDV content of modified CBDV BDS.
Audiogenic seizures in mice
(Experiments 3.1–3.4)
DBA/2 mice were individually placed in a Plexiglas jar (40 cm
wide, 35 cm high) containing an electric bell that sounded
for up to 60 s (110–120 dB) to induce seizure activity (wild
running, clonic convulsions and tonic convulsions), which
was recorded by experienced technicians during experiments
( Jensen et al., 1983).
Isobolographic experimental design and analysis deter-
mines whether two compounds that exert similar (e.g.
anticonvulsant) pharmacological effects behave synergisti-
cally, additively or antagonistically when co-administered
(Tallarida, 2006). Here, this approach was applied using the
audiogenic seizure model to investigate any pharmacological
interactions between CBD and CBDV. Initially, purified CBDV
and CBD (each 10–200 mg·kg−1, i.p.) were administered
separately and their dose–response relationships (DRRs)
calculated for protection against development of clonic
convulsions (Experiment 3.3). CBDV and CBD were then
co-administered in 1:1 effect size ratios (10 equally separated
effect sizes, ED10–ED100) calculated from the previously calcu-
lated DRRs (Experiment 3.4). Thereafter, the individual DRRs
of each pCB were used to create isoboles describing theoreti-
cal lines of additivity at multiple effect sizes (e.g. ED30, ED50)
for the two compounds in combination. Finally, experimen-
tal effect sizes obtained from the co-administration study
were statistically compared with the theoretical line of addi-
tivity on isoboles in accordance with the isobolographic
method for full agonists described by Tallarida (2006).
Motor assays (Experiment 2.2)
Static beam and grip strength tasks were used as described in
Jones et al. (2012) to assess motor function after administra-
tion of unmodified CBDV BDS (150, 275 or 422 mg·kg−1, i.p.),
modified CBDV BDS (150, 275 or 346 mg·kg−1, i.p.) or CBDV
BDS vehicle (control). Treatment order was randomized, and
each animal (n = 10) received all treatments during the study
with a minimum of 48 h between each treatment.
Radioligand binding
Materials. CP55940 was supplied by Tocris (Bristol, UK) and
[3H]CP555940 (160 Ci·mmol−1) by PerkinElmer Life Sciences,
Inc. (Boston, MA, USA).
CHO cells. CHO cells stably transfected with complemen-
tary DNA encoding human CB1 cannabinoid receptors
(PerkinElmer Life Sciences, Inc.) were maintained in DMEM
nutrient mixture F-12 HAM, supplemented with 1 mM
L-glutamine, 10% FBS, 0.6% penicillin-streptomycin and
Geneticin G418 (600 μg·mL−1). Cells were maintained at 37°C
with 5% CO2 and were passaged twice a week using non-
enzymatic cell dissociation solution (EDTA, 1 mM).
Membrane preparation. Binding assays with [3H]CP55940
were performed with membranes obtained from MF1 mouse
whole brain or hCB1-CHO cells (Ross et al., 1999; Thomas
et al., 2004) and frozen as a pellet at −20°C until required.
Before use cells were defrosted, diluted in Tris buffer (50 mM
Tris–HCl and 50 mM Tris–base) and homogenized with a
1 mL handheld homogenizer. Protein assays were performed
using a Bio-Rad DC Kit (Hercules, CA, USA).
Radioligand displacement assay
Assays were carried out in Tris-binding buffer (50 mM Tris–
HCl, 50 mM Tris–base, 0.1% BSA, pH 7.4), total assay volume
500 μL, using the filtration procedure described by Ross et al.
(1999). Binding was initiated by addition of mouse brain
membranes (33 μg protein per well) or hCB1-CHO cell mem-
branes (50 μg protein per well). All assays were performed at
37°C for 60 min before termination by addition of ice cold
Tris-binding buffer and vacuum filtration using a 24 well
sampling manifold (Brandel Cell Harvester; Brandel Inc.,
Gaithersburg, MD, USA) and Brandel GF/B filters that had
been soaked in wash buffer at 4°C for at least 24 h. Each
reaction well was washed six times with Tris-binding buffer
(1.2 mL). The filters were oven-dried for 60 min and placed in
5 mL of scintillation fluid (Ultima Gold XR, PerkinElmer, Seer
Green, Buckinghamshire, UK). Radioactivity was quantified
by liquid scintillation spectrometry. Specific binding was
defined by the presence and absence of 1 μM unlabelled
CP55940. The concentration of [3H]CP55940 used in our
displacement assays was 0.7 nM. All CBDV BDSs and CBDV
were stored as stock solutions (10 mM) in dimethyl sul-
phoxide (DMSO); the vehicle concentration in all assay wells
was 0.1% DMSO. [3H]CP55940 binding parameters were
2336 fmol·mg−1 (Bmax) and 2.31 nM (Kd) in mouse brain mem-
branes (Thomas et al., 2004), and 57.0 pmol·mg−1 (Bmax) and
1.1 nM (Kd) for human CB1 CHO cells.
Statistical analyses
Statistical procedures were performed using GraphPad Prism
5 (GraphPad Software, Inc., San Diego, CA, USA). Effects on
seizure severity were analysed by Kruskal–Wallis with post hoc
Mann–Whitney U-tests. Parameters reported as percentages
were analysed by chi-squared tests with post hoc Fisher exact
tests. Body temperatures were analysed using a Student’s
t-test. Grip strength, distance travelled and foot slips/metre
parameters in motor assays were analysed using one-way
ANOVA with post hoc Tukey tests, performed on the daily aver-
ages of each animal. Isoboles were analysed by comparing the
Cartesian coordinates for the experimental result with those
of the two points on the theoretical line of additivity. The x
coordinate was calculated by setting the y coordinate of the
experimental value and solving for x on the line of additivity,
and vice versa for the y coordinate. The three coordinates
were compared using a chi-squared test. Binding assay values
were expressed as means and variability as SEM or as 95%
confidence limits. The concentrations of test compounds
that produced a 50% displacement of radioligand from
specific binding sites (IC50 values) were determined, and the
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corresponding Ki values were calculated using the equation of
Cheng and Prusoff (1973). All receptor and ion channel
nomenclature conforms to Alexander et al. (2011).
Results
Effects of modified CBDV BDS and
constituents on PTZ-induced seizures in rats
Initially, we investigated the effects of modified CBDV BDS
(containing no Δ9-THCV or Δ9-THC; Table 1) on PTZ-induced
seizures in Experiments 1.1–1.4. The highest modified CBDV
BDS dose was selected to contain the most effective anticon-
vulsant dose of purified CBDV tested to date (200 mg·kg−1;
Hill et al., 2012a). In Experiment 1.1, modified CBDV BDS
had a significant anticonvulsant effect on seizure severity (U
= 13.84, P ≤ 0.05; Figure 1A); 200 and 275 mg·kg−1 signifi-
cantly suppressed the observed severity (P ≤ 0.05). Seizure-
associated mortality was also affected by modified CBDV
BDS administration [χ2(5) = 29.97, P ≤ 0.01; Figure 1B];
≥200 mg·kg−1 significantly reduced mortality (P ≤ 0.05). We
then compared the anticonvulsant effects of modified CBDV
BDS with those of purified CBDV in Experiment 1.2. Admin-
istration of purified CBDV or modified CBDV BDS, matched
by absolute weight, significantly affected the observed seizure
severity (U = 12.72, P ≤ 0.05; Figure 1C); both ≥50 mg·kg−1 of
A B C
D E
G H
F
Figure 1
Effects of CBDV BDS components in the PTZ model of acute convulsion. (A, B) Experiment 1.1: dose response of modified BDS. (C, D) Experiment
1.2: purified CBDV compared with modified BDS. (E, F) Experiment 1.3: comparison of modified CBDV BDS against matching levels of CBDV and
CBD. (G, H) Experiment 1.4: BDS-pCB. (A, C, E, G) Maximum observed convulsion severity (median severity in grey, box represents interquartile
range, whiskers represent maxima and minima (Kruskal–Wallis test, with a post hoc Mann–Whitney U-tests). (B, D, F, H) Mortality (chi-squared test,
with post hoc Fisher exact test); n = 15 for each dose; #P ≤ 0.1, *P ≤ 0.05, **P ≤ 0.01. In all panels ‘V’ represents vehicle treatment.
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purified CBDV (P ≤ 0.05) and 100 mg·kg−1 (P ≤ 0.01) of modi-
fied CBDV BDS significantly suppressed seizure severity; addi-
tionally, 200 mg·kg−1 of modified CBDV BDS produced a
strong trend (P ≤ 0.1) towards seizure severity suppression.
Mortality was also significantly reduced by purified CBDV
and modified CBDV BDS [χ2(6) = 21.05, P ≤ 0.01; Figure 1D],
with significant reductions caused by administration of
≥100 mg·kg−1 (P ≤ 0.01) of either substance.
As 100 mg·kg−1 modified CBDV BDS and purified CBDV
each suppressed seizure activity to a similar extent despite
modified CBDV BDS containing less CBDV, we proceeded to
compare the anticonvulsant properties of the modified CBDV
BDS with combinations of purified CBD and CBDV to assess
potential benefits of BDSs in Experiment 1.3. Administration
of both modified CBDV BDS and matched levels of purified
CBDV plus CBD caused a trend in the observed seizure sever-
ity (U = 12.28, P ≤ 0.1; Figure 1E), where the highest dose of
the purified pCBs (P ≤ 0.05) and middle dose of the modified
CBDV BDS (P ≤ 0.01) significantly suppressed seizure severity.
Mortality was significantly affected by administration of
modified CBDV BDS or matched doses of pCBs [χ2(6) = 26.81,
P ≤ 0.001; Figure 1F], where middle or greater purified pCBs (P
≤ 0.05) and all modified CBDV BDS (P ≤ 0.05) doses signifi-
cantly reduced mortality. In a further experiment (Experi-
ment 1.4), we examined the effects of the BDS-pCB in the PTZ
model of seizure; only a near-significant trend in seizure
severity (U = 6.555, P ≤ 0.1; Figure 1G) was seen due to
100 mg·kg−1, suggesting an increase in seizure severity (P ≤
0.1) but with no effect on mortality (Figure 1H).
Thus, when these data are considered as a whole, modi-
fied CBDV BDS had a strong anticonvulsant effect in the PTZ
model of seizures, producing comparable anticonvulsant
effects as purified constituent pCBs (Figure 1E–G), but with
lower pCB levels.
Effects of modified and unmodified CBDV
BDS on PTZ-induced convulsions and
motor function
Next, we compared modified and unmodified CBDV BDSs to
determine whether the presence of Δ9-THC and Δ9-THCV
affects the anticonvulsant profile of CBDV BDS (Experiment
2.1; Table 1). Administration of both modified and unmodi-
fied CBDV BDS significantly affected the observed seizure
severity (U = 21.57, P ≤ 0.01; Figure 2A); seizure severity was
significantly suppressed by ≥150 mg·kg−1 of both unmodified
(P ≥ 0.05) and modified (P ≥ 0.01) CBDV BDS. Mortality was
also significantly affected by CBDV BDS administration [χ2(6)
= 26.81, P ≤ 0.001; Figure 2B]; 150–275 mg·kg−1 (P ≤ 0.05) of
unmodified and ≥150 mg·kg−1 (P ≤ 0.05) of modified CBDV
BDS significantly reduced mortality.
We next evaluated the effects of modified and unmodified
CBDV BDSs on motor function, using static beam and grip
strength assays (Experiment 2.2; Table 1). CBDV BDS signifi-
cantly affected the number of animals that failed the static
beam [χ2(6) = 15.77, P ≤ 0.05; Figure 2C]; ≥150 mg·kg−1 of
unmodified (P ≤ 0.05) and 346 mg·kg−1 of modified (P ≤ 0.01)
CBDV BDS significantly increased the failure rate. Notably,
the greater failure rate of unmodified CBDV BDS-treated
animals arose from exceeding the time limit. The foot slips/
metre and distance travelled on the static beam were unaf-
fected by either modified or unmodified CBDV BDS, as was
forelimb grip strength. The data presented in Figure 2 taken
as a whole demonstrate that CBDV BDS anticonvulsant activ-
ity is unaffected by the presence or absence of Δ9-THC and
Δ9-THCV. However, poor static beam performance following a
lower dose of unmodified CBDV BDS than modified CBDV
BDS indicates that, despite their opposing pharmacological
actions at CB1 cannabinoid receptors (see the Discussion
section), Δ9-THC and/or Δ9-THCV content negatively affects
motor.
Modified and unmodified CBDV BDSs and
isobolographic analysis of CBDV and CBD in
the audiogenic seizure model
Having demonstrated significant anticonvulsant effects of all
CBDV BDSs in the PTZ model, we next evaluated their anti-
convulsant activity in the audiogenic model of generalized
seizure in mouse (Experiments 3.1 and 3.2).
In Experiment 3.1 (Table 1), the unmodified CBDV BDS
significantly affected the proportion of animals that devel-
oped: wild running [χ2(3) = 19.55, P ≤ 0.001; Figure 3A],
where ≥100 mg·kg−1 significantly reduced incidence (P ≤
0.01); clonic convulsions [χ2(3) = 17.94, P ≤ 0.001; Figure 3A],
where ≥100 mg·kg−1 significantly reduced incidence (P ≤
0.01); and tonic convulsions [χ2(3) = 17.14, P ≤ 0.001;
Figure 3A], where ≥50 mg·kg−1 (P ≤ 0.05) significantly reduced
their incidence. Body temperature was significantly lower in
animals administered 100 mg·kg−1 [36.5°C ± 0.2; t(18) = 3.28,
P ≤ 0.01] and 200 mg·kg−1 [34.5°C ± 0.2; t(18) = 4.78, P ≤
0.001] of unmodified CBDV BDS than vehicle (37.3°C ± 0.1).
Thereafter, we tested the modified CBDV BDS in Experiment
3.2 (Table 1), where administration significantly affected:
wild running [χ2(3) = 26.81, P ≤ 0.001; Figure 3B], where
≥50 mg·kg−1 significantly reduced incidence (P ≤ 0.01); and
clonic convulsions [χ2(3) = 21.18, P ≤ 0.001; Figure 3B], where
≥50 mg·kg−1 (P ≤ 0.05) significantly reduced incidence. Body
temperature was significantly lower in animals administered
200 mg·kg−1 unmodified CBDV BDS [33.7°C ± 0.6; t(18) =
5.73, P ≤ 0.001] when compared with vehicle-treated animals
(37.2°C ± 0.2).
As both modified and unmodified CBDV BDS reduced
seizure activity at lower doses than purified cannabinoids in
the PTZ model of seizure, we also used the tractable nature of
the audiogenic seizure model to investigate any therapeutic
interaction between CBDV and CBD using an isobolographic
approach (Experiments 3.3 and 3.4). Firstly, in Experiment
3.3 we demonstrated that purified CBDV and CBD both
reduced clonic convulsion incidence [χ2(8) = 34.21, P ≤ 0.001;
Figure 3C], where ≥100 mg·kg−1 of both CBDV (P ≤ 0.05) and
CBD (P ≤ 0.05) significantly reduced incidence. Furthermore,
calculation of respective ED50 values revealed that CBDV
(64 mg·kg−1) was more potent than CBD (80 mg·kg−1). The
clonic convulsion parameter was selected to evaluate seizure
suppression due to the linear DRRs, and each dose producing
a unique effect (Tallarida, 2006). As DRRs were significantly
non-parallel [F(1,4) = 121.63, P ≤ 0.01; Figure 3C], in Experi-
ment 3.4 we co-administered CBDV and CBD in a 1:1 dose
effect ratio using 10 theoretical effect sizes (ED10–ED100)
derived from the DRRs of the purified CBDV and CBD in
Figure 3C. The ED50 of co-administered CBDV and CBD did
not differ significantly from the theoretical line of additivity
[χ2(2) = 3.44, P ≥ 0.1; Figure 3D; see the Methods section]
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Figure 2
Anticonvulsant and motor effects of modified and unmodified BDSs. (A, B) Experiment 2.1: effect of BDSs on the severity (A) and associated
mortality (B) of PTZ-induced convulsion. In (A) median severity is shown in grey, box represents interquartile range and whiskers represent maxima
and minima (Kruskal–Wallis test, with a post hoc Mann–Whitney U-tests); in (B), mortality is given as a percentage (chi-squared test, with post hoc
Fisher exact test). (C–F) Experiment 2.2: side effect profile of BDSs in motor assays. (C–E) Performance on the static beam assay showing the failure
rate (C; chi squared, Fisher exact post hoc test), the mean number of foot slips per metre (D) and the mean distance covered (E) after treatment
with BDS or vehicle. (F) Mean forelimb grip strength (kgf). Data in (D–F) presented as mean ± SEM and analysed by ANOVA with Tukey post hoc
test. (A, B) n = 15, (C–F) n = 10; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
BJPCBDV-rich extracts are anticonvulsant
British Journal of Pharmacology (2013) 170 679–692 685
Figure 3
Effects of CBDV BDS modified and unmodified, and isobolographic study of CBDV and CBD. (A, B) Experiments 3.1–3.2: percentage of animals
exhibiting each convulsion parameter (WR, wild running; clonic, clonic convulsions; tonic, tonic convulsions; chi-squared test, with post hoc Fisher
exact test) for unmodified BDS (A) and modified BDS (B). (C–E) Experiments 3.3–3.4: isobolographic determination of CBDV and CBD interactions.
(C) Dose–response relationships of CBD and CBDV. (D) ED50 isobole of CBDV and CBD with theoretical and actual ED50s marked (chi-squared test).
(E) Results from co-administration study and predicted results based on individual pCB studies (two-way ANOVA); n = 10; *P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.001.
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plotted between the ED50s of each drug when administered in
isolation, thereby indicating an additive anticonvulsant
action when the two compounds are combined at this effect
size. Moreover, this additive interaction was present across
the entire dose range, with no significant difference between
the theoretical additive DRR [F(1,9) = 0.49, P ≥ 0.1; Figure 3E],
derived from the pCBs in isolation, and the experimental
DRR follows co-administration.
As a whole, these results demonstrate that modified and
unmodified CBDV BDSs each have strong anticonvulsant
activity in the mouse audiogenic seizure and complement
the data produced in the PTZ seizure model. In addition, we
demonstrate that anticonvulsant properties of CBDV and
CBD are additive in the mouse audiogenic seizure model.
Effects of CBDV BDSs on pilocarpine-induced
convulsions in rats
Both modified and unmodified CBDV BDSs were investigated
in the pilocarpine model of acute, temporal lobe convulsion
(Experiments 4.1 and 4.2; Table 1). In Experiment 4.1,
unmodified CBDV BDS significantly affected convulsion
severity (U = 13.15, P ≤ 0.01; Figure 4A); ≥100 mg·kg−1 signifi-
cantly reduced severity (P ≥ 0.05). No effect on mortality was
observed (data not shown). In Experiment 4.2, using the dose
at which unmodified CBDV BDS exerted its optimal anticon-
vulsant effect (200 mg·kg−1; see Figure 4A), the effects of
modified and unmodified CBDV BDSs and co-administered
purified pCBs with matching doses of CBDV and CBD were
compared. Drug treatment significantly affected convulsion
severity (U = 10.64, P ≤ 0.05; Figure 4A); unmodified CBDV
BDS (P ≤ 0.05) and purified pCBs (P ≤ 0.001) reduced severity,
and modified CBDV BDS produced a trend towards severity
reduction (P ≤ 0.1). Drug administration produced a trend
towards a reduction in mortality [χ2(3) = 6.67, P ≤ 0.1], where
unmodified CBDV BDS reduced mortality (P ≤ 0.1; data not
shown).
Radioligand binding assays
First, displacement binding assays to compare the pharmaco-
logical profiles of unmodified CBDV BDS with purified CBDV
were performed. Unmodified CBDV BDS showed greater
affinity for CB1 cannabinoid receptors than purified CBDV in
both MF1 mouse brain and hCB1-CHO cell membranes
(Figure 5A,B and Table 2); purified CBDV only displaced
[3H]CP55940 at the highest concentration tested (10 μM).
Next, to investigate the greater affinity of unmodified CBDV
BDS over purified CBDV for CB1 cannabinoid receptors, dis-
placement binding assays using MF1 whole brain membranes
were performed with unmodified CBDV BDS in parallel with
the modified CBDV BDS. Interestingly, removal of Δ9-THC
and Δ9-THCV did not significantly affect the potency with
which modified CBDV BDS displaced [3H]CP55940 (Figure 5C
and Table 2). However, the mean displacement, at the highest
concentrations tested (1 and 10 μM), was significantly
reduced by this removal (P < 0.05) (Figure 5C and Table 2). To
further assess the contribution made by Δ9-THC plus Δ9-THCV
to the potency with which unmodified CBDV BDS displaced
[3H]CP55940, we tested unmodified CBDV BDS in parallel
with BDS-pCB to which a pCB (CBDV, Δ9-THCV or Δ9-THC)
had been added. The resulting percentage concentration of
the added pCB was the same as the percentage concentration
of this pCB in unmodified CBDV BDS. Interestingly, we found
A B
Figure 4
Modified and unmodified CBDV BDS, and purified cannabinoids in the acute pilocarpine model in rat. (A) Experiment 4.1: unmodified CBDV BDS.
(B) Experiment 4.2: modified and unmodified CBDV BDS, and matched doses of pure CBDV and CBD. Both panels show maximum observed
seizure severity (median severity in grey, box represents interquartile range, whiskers represent maxima and minima; Kruskal–Wallis test, with a
post hoc Mann–Whitney U-tests). n = 15; #P ≤ 0.1, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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that BDS-pCB + purified CBDV displaced [3H]CP55940 with
significantly less potency than unmodified CBDV BDS
(Figure 5D and Table 3). The addition of Δ9-THCV to BDS-pCB
resulted in this BDS displacing [3H]CP55940 with slightly, but
not significantly, less potency than unmodified CBDV BDS
(Figure 5E and Table 3). Addition of Δ9-THC had no statisti-
cally significant effect on the potency or maximum percent-
age of displacement with which unmodified CBDV BDS
displaced [3H]CP55940 from mouse brain membranes
(Figure 5F and Table 3). Taken together, these results suggest
that both Δ9-THC and Δ9-THCV together in the unmodified
CBDV BDS accounts for its ability to displace [3H]CP55940
with greater potency than purified CBDV from specific
binding sites in membranes from both MF1 whole brain and
human CB1-CHO cells.
Discussion
Here, for the first time, we demonstrate that cannabis extracts
rich in CBDV and CBD can exert significant anticonvulsant
effects. Importantly, these effects were observed in three sepa-
rate models of seizure across two species. Both the modified
and the unmodified CBDV BDSs had broadly similar efficacies
Figure 5
Radioligand binding properties of CBDV BDSs. Displacement of [3H]CP55940 by pure CBDV and unmodified CBDV BDS from (A) specific binding
sites on MF1 mouse brain membranes and (B) hCB1-CHO cell membranes. Displacement of [3H]CP55940 by (C) unmodified CBDV BDS and
modified CBDV BDS, (D) unmodified CBDV BDS and BDS-pCB plus pure CBDV, (E) unmodified CBDV BDS and BDS-pCB plus purified Δ9-THCV,
and (F) unmodified CBDV BDS and BDS-pCB plus purified Δ9-THC from specific binding sites on MF1 mouse brain membranes. Symbols represent
mean values ± SEM. Modified CBDV BDS lacks both Δ9-THC and Δ9-THCV. n = 4 in all cases.
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to purified CBDV as well as CBDV and CBD in combination.
Thereafter, we determined that CBDV and CBD act together
in an additive manner against audiogenic seizures. While the
presence of Δ9-THC and Δ9-THCV in the extracts did not affect
anticonvulsant profile, their presence adversely affected
motor function and was responsible for the displacement of
CB1 cannabinoid receptor ligands in radioligand binding
assays. Additionally, this is the first study to examine CBDV
binding at the CB1 cannabinoid receptor where affinity was
found to be very limited.
Anticonvulsant effects of CBDV BDSs
The modified CBDV BDS was investigated first as Δ9-THC at
sufficiently high doses can induce psychoactive effects via the
CB1 cannabinoid receptor, an undesirable clinical side effect.
Although Δ9-THCV, a neutral CB1 cannabinoid receptor
antagonist, can exert limited anticonvulsant effects, the clini-
cal profile of such compounds remains unclear but is likely to
be distinct from that of inverse agonists, for example,
rimonabant (Pertwee, 2005).
Modified CBDV BDS dose-dependently reduced seizure
severity and mortality, clearly demonstrating that the modi-
fied CBDV BDS was anticonvulsant. When purified CBDV
and the modified CBDV BDS were compared, both reduced
seizure severity and mortality; CBDV affected severity at a
lower dose than modified CBDV BDS, but doses suppressing
mortality were comparable. Subsequently, instead of compar-
ing by absolute weight to the principal pCB, we compared by
CBDV and CBD content to see if co-administered CBDV and
CBD further reduced seizure severity, a broadly similar anti-
convulsant effect resulted. In addition, modified CBDV BDS
significantly reduced mortality at a lower dose than purified
pCBs, a possible benefit of the BDS over purified pCBs.
However, in Experiments 1.1–1.3 and 2.1, the highest doses
of both the modified and the unmodified CBDV BDSs did not
appear as efficacious as the preceding dose. While a definitive
cause for this remains to be determined, this effect was not
due to any significant pro-convulsant activity of the non-
cannabinoid fraction (see Experiment 1.4). However, the
complex nature (∼400 discrete non-cannabinoid constitu-
ents) of standardized cannabis extracts (Elsohly and Slade,
2005) means that concentrations of some constituents that
could affect cannabinoid pharmacokinetics might only
appear at higher doses to produce the differences seen.
Overall, these results indicate that CBDV BDS could be
efficacious in the treatment of generalized seizures (Löscher,
2011), and its anticonvulsant activity against PTZ-induced
Table 2
Displacement of [3H]CP55940 by (A) pure CBDV and unmodified CBDV BDS, and (B) unmodified CBDV BDS and modified CBDV BDS from specific
binding sites on MF1 brain membranes
Experiment Compound Ki (nM) (95% CL)
Maximum %
displacement (95% CL) n
A* Pure CBDV No plateau – 4
A* Unmodified CBDV BDS 127.6 (52.5 and 310.2) 113.6 (98.2 and 129.0) 4
B Unmodified CBDV BDS 722.6 (403.7 and 1293) 98.6 (83.8 and 113.4) 4
B Modified CBDV BDS 1010 (223.5 and 4564) 55.5 (33.4 and 77.6) 4
*Mean Ki and maximum % displacement values for pure CBDV and unmodified CBDV BDS in hCB1-CHO cell membranes were not
significantly different from those obtained in MF1 whole mouse brain membranes (see Results and Figure 5A,B).
CL, confidence limit.
Table 3
Displacement of [3H]CP55940 by (A) unmodified CBDV BDS and BDS-pCB + pure CBDV, (B) unmodified CBDV BDS and BDS-pCB + pure THCV,
and (C) unmodified CBDV BDS and BDS-pCB + pure THC from specific binding sites on MF1 brain membranes
Experiment Compound Ki (nM) (95% CL)
Maximum %
displacement (95% CL) n
A Unmodified CBDV BDS 300.8 (159.2 and 568.5) 89.2 (78.7 and 99.7) 4
A BDS-pCB + pure CBDV 2151 (643.9 and 7184) 80.2 (51.8 and 108.6) 4
B Unmodified CBDV BDS 363.9 (141.4 and 936.5) 85.8 (70.4 and 101.3) 4
B BDS-pCB + pure THCV 960.0 (203.8 and 4523) 73.0 (44.6 and 101.3) 4
C Unmodified CBDV BDS 604.5 (252.5 and 1447) 99.5 (79.7 and 119.3) 4
C BDS-pCB + pure THC 861.7 (195.1 and 3805) 86.5 (57.4 and 115.6) 4
CL, confidence limit.
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seizures justifies further investigation of its utility against
absence seizures using absence epilepsy models such as the
GAERS and WAG/Rij rats (Coenen et al., 1992; Marescaux and
Vergnes, 1995; Hosford and Wang, 1997).
Both unmodified and modified CBDV BDS reduced
seizure severity when compared directly, with little appreci-
able difference in efficacy in the PTZ model. However, when
the static beam task was employed to evaluate any motor side
effects of the modified and unmodified CBDV BDSs, a drug-
induced increase in the number of animals failing the task
was seen. This effect was observed for all doses of unmodified
CBDV BDS, but only the highest dose of modified CBDV BDS,
suggesting that Δ9-THC and/or Δ9-THCV were responsible for
a significant proportion of the observed motor deficits. The
majority of unmodified CBDV BDS-treated animals failed due
to the task’s 5 min time limit being exceeded as animals
remained stationary. This is consistent with previous reports
on the effects of Δ9-THC on motor function (Järbe et al., 2002)
and further suggests that the Δ9-THCV present in the unmodi-
fied CBDV BDS may have been insufficient to overcome
Δ9-THC-mediated CB1 cannabinoid receptor partial agonism.
In contrast to the effects on static beam performance, neither
CBDV BDS elicited grip strength deficits, a test for muscle
relaxation (Nevins et al., 1993) and, putatively, functional
neurotoxicity (Sed et al., 2008). Many currently available
AEDs produce notable side effects in people with epilepsy,
including motor function deficits (Schachter, 2007), which
reduce quality of life. These deficits are often also seen in
non-clinical species (Löscher, 2011), potentially reducing the
observed seizure severity in models of seizure (Hill et al.,
2012a).
Cannabinoid and non-cannabinoid
interactions in BDS
Cannabis-based BDSs have been reported to possess different
pharmacological activity to their principal pCB constituent,
where the presence of the non-principal pCBs and pCB-free
fraction can enhance or decrease activity in some in vitro
assays (De Petrocellis et al., 2011). Given this a priori knowl-
edge and because the results obtained from our comparisons
of CBDV BDS and purified pCB effects in seizure models
suggested possible advantages of CBDV BDSs, we also inves-
tigated the actions and interactions of the pCB and pCB-free
components of CBDV BDSs. Importantly, we showed that the
BDS-pCB exerted no significant effect upon seizure severity in
the PTZ model of seizure. In order to investigate interactions
between CBDV and CBD, we employed the mouse audiogenic
seizure model. Prior to the isobolographic study, we con-
firmed a dose-dependent anticonvulsant effect of the modi-
fied and unmodified CBDV BDSs in the audiogenic model
comparable to that in PTZ. A core temperature below 34.5°C
in DBA/2 mice can reduce seizure incidence in the audiogenic
model (Essman and Sudak, 1964); however, significant reduc-
tions in seizure severity were seen in animals with body
temperatures higher than this threshold, indicating that anti-
convulsant effects were not primarily due to hypothermia.
Using the isobolographic study design, we demonstrated an
additive anticonvulsant effect of purified CBDV and CBD
co-administration; there were no deleterious effects from
co-administering these pCBs.
We have previously reported that administration of
≤200 mg·kg−1 CBDV did not produce anticonvulsant effects in
the pilocarpine model (Hill et al., 2012a) except in highly
powered experiments (n = 60 CBDV-treated animals), and
that CBD did not affect convulsion severity in this model
despite reduced tonic–clonic seizure incidence ( Jones et al.,
2012). In contrast, here we have demonstrated that
≥116 mg·kg−1 CBDV and ≥27 mg·kg−1 CBD co-administered as
unmodified CBDV BDS or a combination of purified pCBs
significantly reduced convulsion severity, demonstrating a
clear advantage to combinatorial use of CBDV and CBD to
treat temporal lobe convulsions in this model.
CB1 cannabinoid receptor binding of
CBDV BDSs
In MF1 mouse whole brain membranes, we found that
unmodified CBDV BDS showed greater affinity for CB1 can-
nabinoid receptors than purified CBDV, with mean Ki and
maximum percentage displacement values not significantly
different from those obtained using CHO cells over-
expressing the human CB1 cannabinoid receptor. Purified
CBDV had little affinity for CB1 cannabinoid receptors, with
only the highest concentration tested (10 μM) exhibiting an
effect. Our results suggest that the unmodified CBDV BDS’s
higher potency is due to its ability to bind to CB1 receptors,
and not other GPCRs present in the brain. Unmodified CBDV
BDS contains a significant percentage of CBD, Δ9-THC and
Δ9-THCV. Although we and others have reported that CBD
binds to CB1 receptors with only very weak affinity (mean Ki
values in the micromolar range; Pertwee, 2008), both Δ9-THC
and Δ9-THCV are potent CB1 cannabinoid receptor ligands
(mean Ki values in the nanomolar range; Pertwee, 2008).
Interestingly we found that (i) although the modified CBDV
BDS’s affinity was not significantly affected by the removal of
Δ9-THC and Δ9-THCV, its maximum percentage displacement
was significantly lower than that of unmodified CBDV BDS;
(ii) the addition of Δ9-THC or Δ9-THCV to the BDS-pCB had
no statistically significant effect on the ability of this BDS to
displace [3H]CP55940 from mouse brain membranes com-
pared with unmodified CBDV-BDS. In contrast (Figure 5D),
the BDS-pCB plus CBDV mixture displaced [3H]CP55940 with
significantly less potency than unmodified CBDV-BDS, and is
consistent with our finding that purified CBDV binds to CB1
cannabinoid receptors with only very weak affinity (limited
effect and no plateau was reached at the highest concentra-
tion tested). Together, these in vitro results suggest that the
presence of both Δ9-THC and Δ9-THCV accounts for the
ability of unmodified CBDV BDS to displace [3H]CP55940
with higher affinity than purified CBDV. Furthermore, as
modified and unmodified CBDV BDS display a similar anti-
convulsant action in vivo, the binding data suggest that the
anticonvulsant mechanism of action of the CBDV BDSs are
not CB1 cannabinoid receptor mediated. Despite CBD inhib-
iting ion channel function (e.g. T-type Ca2+ channels; Ross
et al., 2008) and increasing inhibitory activity at some GPCRs
(e.g. 5-HT1A; Russo et al., 2005), the specific molecular
target(s) underlying CBD’s anticonvulsant effects remain
unconfirmed (Hill et al., 2012b). While limited structural
changes can profoundly affect cannabinoid pharmacology
(e.g. Δ9-THC and Δ9-THCV at CB1 cannabinoid receptors), it is
not unreasonable to suggest that CBDV may share some
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pharmacological properties with CBD. CBD and CBDV have
agonist effects at TRPA1, TRPV1 and TRPV2 receptors, and
antagonistic properties at TRPM8 (De Petrocellis et al., 2011).
Although TRPV1 expression has been reported in the brain
(Tóth et al., 2005), as with other TRP receptors to which
CBDV can bind, its functional role in health and disease is
unclear. CBDV has also been reported to inhibit diacyl-
glycerol lipase-α (De Petrocellis et al., 2011), an enzyme
responsible for the synthesis of the endocannabinoid,
2-arachidonoylglycerol, and to stimulate fibroblast formation
via a mechanism that can be functionally blocked by concur-
rent CB2 cannabinoid receptor antagonism (Scutt and
Williamson, 2007). However, no evidence yet exists to link
any of these mechanisms to CBDV’s anticonvulsant activity.
Conclusions
In conclusion, these results demonstrate a strong CB1 can-
nabinoid receptor-independent anticonvulsant action of
both modified and unmodified CBDV BDSs in three models
of seizure, across two species. While unmodified CBDV BDS
negatively affected performance in one motor function task,
this was in stark contrast to the modified CBDV BDS that was
well tolerated at anticonvulsant doses. This indicates that
both modified and unmodified CBDV BDSs have potential to
treat generalized or temporal lobe seizures with the modified
CBDV BDS being best tolerated.
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